Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer

International Journal of Radiation Oncology Biology Physics

Volumn 82, Issue 2, 2012, Pages 877-882

  King, Christopher R ^a   Brooks, James D ^b   Gill, Harcharan ^b   Presti, Joseph C ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hypofractionation; Prostate cancer; PSA; Stereotactic body radiotherapy; Toxicity

Indexed keywords

ANTIGENS; DISEASES; ONCOLOGY; RADIOTHERAPY; TUMORS; UROLOGY;

FOLLOW UP; HYPOFRACTIONATED RADIOTHERAPIES; HYPOFRACTIONATION; LONG-TERM OUTCOME; PROSPECTIVES; PROSTATE CANCERS; PROSTATE SPECIFIC ANTIGEN; RADIATION THERAPY ONCOLOGY GROUPS; RECTAL TOXICITY; STEREOTACTIC BODY RADIOTHERAPY;

TOXICITY;

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER SURVIVAL; CYBERKNIFE; DISEASE EXACERBATION; DYSURIA; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RECTUM DISEASE; RECURRENCE FREE SURVIVAL; STEREOTACTIC BODY RADIATION THERAPY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 84855825726     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2010.11.054     Document Type: Article

References (26)

1. A. Dasu Is the α/β value for prostate tumours low enough to be safely used in clinical trials? Clin Oncol 19 2007 289 301
2. J.F. Fowler, M.A. Ritter, R.J. Chappell, and D.J. Brenner What hypofractionated protocols should be tested for prostate cancer? Int J Radiat Oncol Biol Phys 56 2003 1093 1104
3. E.E. Yeoh, R.H. Holloway, and R.J. Fraser Hypofractionated vs. conventionally fractionated radiation therapy for prostate carcinoma: Updated results of a Phase III randomized trial Int J Radiat Oncol Biol Phys 66 2006 1072 1083
4. H. Lukka, C. Hayter, and J.A. Julian Randomized trial comparing two fractionation schedules for patients with localized prostate cancer J Clin Oncol 23 2005 6132 6138
5. P.A. Kupelian, T.R. Willoughby, and C.A. Reddy Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience Int J Radiat Oncol Biol Phys 68 2007 1424 1430
6. J.E. Livsey, R.A. Cowan, and J.P. Wylie Hypofractionated conformal radiotherapy in carcinoma of the prostate: Five-year outcome analysis Int J Radiat Oncol Biol Phys 57 2003 1254 1259
7. R.W. Lloyd-Davies, C.D. Collins, and A.V. Swan Carcinoma of prostate treated by radical external beam radiotherapy using hypofractionation. Twenty-two years' experience (1962-1984) Urology 36 1990 107 111
8. Yoshioka Y, Konishi K, Sumida I, et al. Monotherapeutic high-dose-rate brachytherapy for prostate cancer: Five-year results of an extreme hypofractionation regimen with 54 gy in nine fractions. Int J Radiat Oncol Biol Phys. In press.
9. A.A. Martinez, J. Demanes, and C. Vargas High-dose-rate prostate brachytherapy: An excellent accelerated-hypofractionated treatment for favorable prostate cancer Am J Clin Oncol 33 2010 481 488
10. B.L. Madsen, R.A. Hsi, and H.T. Pham Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized prostate disease: First clinical trial results Int J Radiat Oncol Biol Phys 67 2007 1099 1105
11. C.R. King, J.D. Brooks, and H. Gill Stereotactic body radiotherapy for localized cancer: Interim results of a prospective Phase II clinical trial Int J Radiat Oncol Biol Phys 73 2009 1043 1048
12. A.J. Katz, M. Santoro, and R. Ashley Stereotactic body radiotherapy for organ-confined prostate cancer BMC Urol 10 2010 1
13. Townsend NC, Huth BJ, Ding W, et al. Acute toxicity after CyberKnife-delivered hypofractionated radiotherapy for treatment of prostate cancer. Am J Clin Oncol. In press.
14. F.L. Greene, D.L. Page, and I.D. Flemming AJCC Manual for staging cancer 6th ed. 2002 Springer Verlag New York p. 309-313
15. Common toxicity criteria (Version 2.0) 1998 National Institutes of Health Bethesda, MD
16. S.T.H. Peeters, W.D. Heemsbergen, and P.C.M. Koper Dose-Response in radiotherapy for localized prostate cancer: Results of the Dutch Multicenter Randomized Phase III Trial comparing 68 Gy of radiotherapy with 78 Gy J Clin Oncol 24 2006 1990 1996
17. D.A. Kuban, S.L. Tucker, and L. Dong Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer Int J Radiat Oncol Biol Phys 70 2008 67 74
18. A.L. Zietman, K. Bae, and J.D. Slater Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: Long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09 J Clin Oncol 28 2010 1106 1111
19. D.P. Dearnley, M.R. Sydes, and J.D. Graham Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First RESULTS from the MRC RT01 Randomized Controlled Trial Lancet Oncol 8 2007 475 487
20. P.A. Kupelian, T.R. Willoughby, and C. Reddy Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience Int J Radiat Oncol Biol Phys 68 2007 1424 1430
21. J.M. Martin, T. Rosewall, and A. Bayley Phase II trial of hypofractionated image-guided intensity modulated radiotherapy for localized prostate adenocarcinoma Int J Radiat Oncol Biol Phys 69 2007 1084 1089
22. J.H. Coote, J.P. Wylie, and R.A. Cowan Hypofractionated intensity-modulated radiotherapy for carcinoma of the prostate: Analysis of toxicity Int J Radiat Oncol Biol Phys 74 2009 1121 1127
23. Lock M, Best L, Wong E, et al. A Phase II trial of arc-based hypofractionated intensity-modulated radiotherapy in localized prostate cancer. Int J Radiat Oncol Biol Phys. In press
24. M.J. Zelefsky, H. Chan, and M. Hunt Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer J Urol 176 2006 1415 1419
25. S.P. Elliott, M.V. Meng, and E.P. Elkin Incidence of urethral stricture after primary treatment for prostate cancer: Data from CaPSURE J Urol 178 2007 529 534
26. M.S. Katz, J.A. Efstathiou, and A.V. D'Amico The "CaP Calculator": An online decision support tool for clinically localized prostate cancer BJU Int 105 2010 1417 1422